0001225208-20-003559.txt : 20200226 0001225208-20-003559.hdr.sgml : 20200226 20200226162414 ACCESSION NUMBER: 0001225208-20-003559 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200224 FILED AS OF DATE: 20200226 DATE AS OF CHANGE: 20200226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ballinger Kevin J. CENTRAL INDEX KEY: 0001566080 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 20656071 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2020-02-24 0000885725 BOSTON SCIENTIFIC CORP BSX 0001566080 Ballinger Kevin J. 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP & Pres, Interven Cardio Common Stock 2020-02-25 4 S 0 5658.0000 41.1500 D 95868.0000 D Performance Share Units 2020-02-24 4 A 0 10666.0000 0.0000 A 2021-12-31 2021-12-31 Common Stock 10666.0000 10666.0000 D This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. /s/ Scott G. Hodgdon, Attorney-in-Fact 2020-02-26